Substance / Medication

Micafungin

Overview

Active Ingredient
micafungin
RxNorm CUI
325887

Indications

Micafungin for injection is indicated for: Limitations of Use • Candida 14.1 8.4 [see Clinical Studies () and Use in Specific Populations ()] Treatment of Candidemia, Acute Disseminated Candidiasis,Peritonitis and Abscesses in adult and pediatric patients 4 months of age and older • Candida without 8.4 [see Use in Specific Populations ()] Treatment of Candidemia, Acute Disseminated Candidiasis,Peritonitis and Abscessesmeningoencephalitis and/or ocular dissemination in pediatric patients younger

Labeler: Glenmark Pharmaceuticals Inc., USAUpdated: 2025-09-09T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

Micafungin for injection is contraindicated in persons with known hypersensitivity to micafungin, any component of micafungin for injection, or other echinocandins.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

9 trials linked to this intervention

9
Total Trials
0
Recruiting
3
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Newer antifungal agents micafungin and voriconazole for fungal infection prevention during hematopoietic cell transplantation: a meta-analysis.
Xu S-X, Shen J-L, Tang X-F et al. · Eur Rev Med Pharmacol Sci · 2016
PMID: 26875911Meta-Analysis
Efficacy and safety of micafungin for invasive candida infections: a meta-analysis of randomized controlled trials.
Chen Qian, Lin Mao-Hu, Chen Meng-Li et al. · Chin Med J (Engl) · 2012
PMID: 22340571Meta-Analysis
Safety of micafungin in pediatric clinical trials.
Arrieta Antonio C, Maddison Philip, Groll Andreas H · Pediatr Infect Dis J · 2011
PMID: 21378595Meta-Analysis
[Future role of micafungin in the treatment of invasive mycoses caused by filamentous fungi].
Salavert-Lletí Miguel, Zaragoza-Crespo Rafael · Rev Iberoam Micol · 2009
PMID: 19463284Meta-Analysis
[Pharmacodynamics and pharmacokinetics of micafungin in adults, children and neonate].
Catalán-González Mercedes, Carlos Montejo-González Juan · Rev Iberoam Micol · 2009
PMID: 19463274Meta-Analysis
Population pharmacokinetics of micafungin and its metabolites M1 and M5 in children and adolescents.
Hope William W, Kaibara Atsunori, Roy Michael et al. · Antimicrob Agents Chemother · 2015
PMID: 25421470RCTFull text (PMC)
Economic evaluation of micafungin versus caspofungin for the treatment of candidaemia and invasive candidiasis.
Neoh C F, Liew D, Slavin M A et al. · Intern Med J · 2013
PMID: 23461421RCT

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Micafungin (substance)
SNOMED CT
416127003
UMLS CUI
C1120386
RxNorm CUI
325887
Labeler
Glenmark Pharmaceuticals Inc., USA

Clinical Data

This intervention maps to 2 entities in the Ltrl knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
9
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.